Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.
暂无分享,去创建一个
[1] B. Rowan,et al. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer , 2015, Molecular and Cellular Endocrinology.
[2] Zhaoyi Wang,et al. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer , 2015, Molecular and Cellular Endocrinology.
[3] J. Węsierska‐Gądek,et al. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells , 2015, Journal of cellular biochemistry.
[4] N. Ibrahim,et al. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer , 2015, Investigational New Drugs.
[5] Agnieszka K. Witkiewicz,et al. The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.
[6] D. Heitjan,et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.
[7] S. Yaccoby,et al. Dinaciclib, a CDK Inhibitor, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition , 2014 .
[8] C. Shapiro,et al. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. , 2014, Clinical breast cancer.
[9] T. Hong,et al. Slug is temporally regulated by cyclin E in cell cycle and controls genome stability , 2014, Oncogene.
[10] M. Scharfe,et al. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-κB-dependent gene expression. , 2014, Molecular cell.
[11] J. Nemunaitis,et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies , 2013, Journal of Translational Medicine.
[12] M. Malumbres,et al. A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis , 2013, Cancer cell.
[13] R. Sutherland,et al. Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1 , 2013, Cell cycle.
[14] R. Sutherland,et al. Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells , 2013, Cell cycle.
[15] Marc E. Lenburg,et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.
[16] J. Węsierska‐Gądek,et al. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications , 2011, Expert opinion on investigational drugs.
[17] J. Baselga,et al. Targeted therapies for breast cancer. , 2011, The Journal of clinical investigation.
[18] J. Gustafsson,et al. The different roles of ER subtypes in cancer biology and therapy , 2011, Nature Reviews Cancer.
[19] J. Węsierska‐Gądek,et al. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen‐induced phosphorylation of ER‐α in human ER‐positive breast cancer cells , 2011, Journal of cellular biochemistry.
[20] M. Lai,et al. Translational control of cyclins , 2011, Cell Division.
[21] E. Lees,et al. Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.
[22] K. Keyomarsi,et al. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. , 2010, Cancer research.
[23] K. Hunt,et al. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. , 2010, Cancer research.
[24] R. Sutherland,et al. Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer , 2010, Cell cycle.
[25] Yan Liu,et al. A Novel Interaction Between HER2/neu and Cyclin E in Breast Cancer , 2010, Oncogene.
[26] K. Gelmon,et al. Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.
[27] J. Hartman,et al. Hes-6, an inhibitor of Hes-1, is regulated by 17β-estradiol and promotes breast cancer cell proliferation , 2009, Breast Cancer Research.
[28] J. Węsierska‐Gądek,et al. Selective Cyclin‐Dependent Kinase Inhibitors Discriminating between Cell Cycle and Transcriptional Kinases , 2009, Annals of the New York Academy of Sciences.
[29] J. Carroll,et al. Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc , 2009, Molecular and Cellular Biology.
[30] J. Węsierska‐Gądek,et al. Functional p53 in cells contributes to the anticancer effect of the cyclin‐dependent kinase inhibitor roscovitine , 2009, Journal of cellular biochemistry.
[31] Megan Coleman,et al. Estrogen receptor‐alpha (ER‐α) suppresses expression of its variant ER‐α36 , 2009, FEBS letters.
[32] J. Węsierska‐Gądek,et al. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment , 2009, Journal of cellular biochemistry.
[33] M. Shupnik,et al. ERβ in breast cancer—Onlooker, passive player, or active protector? , 2008, Steroids.
[34] J. Gustafsson,et al. Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues , 2008, Journal of internal medicine.
[35] Andrew R. Green,et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.
[36] James M. Roberts,et al. CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .
[37] S. Tucker,et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. , 2007, Cancer research.
[38] C. Nerlov,et al. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1‐C/EBPα interaction , 2007, The EMBO journal.
[39] Urs Eppenberger,et al. Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer , 2007, BMC Cancer.
[40] V. Jordan,et al. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer , 2007, Steroids.
[41] A. Thompson,et al. Cyclin D1 and breast cancer. , 2006, Breast.
[42] C. Sotiriou,et al. Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients , 2006, International journal of cancer.
[43] M. Barton,et al. Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer , 2006, Journal of cellular physiology.
[44] A. Hill,et al. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. , 2006, Endocrine-related cancer.
[45] David G Johnson,et al. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. , 2006, Current molecular medicine.
[46] K. Nakayama,et al. Ubiquitin ligases: cell-cycle control and cancer , 2006, Nature Reviews Cancer.
[47] Robin L. Jones,et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.
[48] E. Kubista,et al. Proteomic analysis in human breast cancer: Identification of a characteristic protein expression profile of malignant breast epithelium , 2006, Proteomics.
[49] P. Hinds,et al. From Cell Cycle to Differentiation: An Expanding Role for Cdk6 , 2006, Cell cycle.
[50] M. Kampa,et al. Activation of membrane estrogen receptors induce pro-survival kinases , 2006, The Journal of Steroid Biochemistry and Molecular Biology.
[51] Robert L Sutherland,et al. Cell cycle control in breast cancer cells , 2006, Journal of cellular biochemistry.
[52] T. Deuel,et al. Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66 , 2005 .
[53] M. Barbacid,et al. Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.
[54] V. Notario,et al. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. , 2005, Cancer research.
[55] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[56] K. Hunt,et al. Cyclin E as a prognostic and predictive marker in breast cancer. , 2005, Seminars in Cancer Biology.
[57] A. Papanikolaou,et al. Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] T. Willson,et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. , 2005, Molecular cell.
[59] D. Cobrinik. Pocket proteins and cell cycle control , 2005, Oncogene.
[60] Eric R. Prossnitz,et al. A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling , 2005, Science.
[61] J. Węsierska‐Gądek,et al. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. , 2005, Molecular cancer therapeutics.
[62] D. Fan,et al. Inhibition of gastric cancer angiogenesis by vector-based RNA interference for Raf-1 , 2005, Cancer biology & therapy.
[63] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[64] Pierre Dubus,et al. Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.
[65] Bruce Stillman,et al. Deregulation of cyclin E in human cells interferes with prereplication complex assembly , 2004, The Journal of cell biology.
[66] T. T. Su,et al. Promiscuity Rules? The Dispensability of Cyclin E and Cdk2 , 2004, Science's STKE.
[67] Anne-Marie Brun-Zinkernagel,et al. Mitochondrial localization of estrogen receptor β , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[68] A. Wellstein,et al. Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway , 2003, Oncogene.
[69] J. Gustafsson,et al. Estrogen signaling: a subtle balance between ER alpha and ER beta. , 2003, Molecular interventions.
[70] T. Jacks,et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry , 2003, Nature.
[71] J. Frasor,et al. Response-Specific and Ligand Dose-Dependent Modulation of Estrogen Receptor (ER) α Activity by ERβ in the Uterus , 2003 .
[72] I. Bedrosian,et al. The Low Molecular Weight Isoforms of Cyclin E Deregulate the Cell Cycle of Mammary Epithelial Cells , 2003, Cell cycle.
[73] A. Wellstein,et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. , 2003, Molecular endocrinology.
[74] L. Hartmann,et al. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.
[75] K. Dahlman-Wright,et al. Estrogen Receptor (ER)-β Reduces ERα-Regulated Gene Transcription, Supporting a “Ying Yang” Relationship between ERα and ERβ in Mice , 2003 .
[76] D. Lannigan. Estrogen receptor phosphorylation , 2003, Steroids.
[77] P. Driggers,et al. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling , 2002, Trends in Endocrinology & Metabolism.
[78] F. Lallemand,et al. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells , 2002, Oncogene.
[79] Isabelle Bedrosian,et al. Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.
[80] Simak Ali,et al. Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.
[81] A. Bilancio,et al. PI3‐kinase in concert with Src promotes the S‐phase entry of oestradiol‐stimulated MCF‐7 cells , 2001, The EMBO journal.
[82] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[83] D. Márquez,et al. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells , 2001, Oncogene.
[84] Mollianne J. McGahren,et al. Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms , 2001, Molecular and Cellular Biology.
[85] S. Safe,et al. Differential gene expression in response to methoxychlor and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[86] S. Safe,et al. Estrogen Regulation of Cyclin D1 Gene Expression in ZR-75 Breast Cancer Cells Involves Multiple Enhancer Elements* , 2001, The Journal of Biological Chemistry.
[87] E. Levin,et al. Rapid actions of plasma membrane estrogen receptors , 2001, Trends in Endocrinology & Metabolism.
[88] J. Thomsen,et al. Mechanisms of estrogen action. , 2001, Physiological reviews.
[89] K. Bland,et al. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. , 2000, Molecular endocrinology.
[90] J. Harbour,et al. The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.
[91] Simak Ali,et al. Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance , 2000, Journal of Mammary Gland Biology and Neoplasia.
[92] Simak Ali,et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. , 2000, Molecular cell.
[93] K. Keyomarsi,et al. Processing of cyclin E differs between normal and tumor breast cells. , 2000, Cancer research.
[94] T. David-Pfeuty. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells , 1999, Oncogene.
[95] J. Mester,et al. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[96] S. Reed,et al. Deregulated cyclin E induces chromosome instability , 1999, Nature.
[97] M. Garabedian,et al. Potentiation of Human Estrogen Receptor α Transcriptional Activation through Phosphorylation of Serines 104 and 106 by the Cyclin A-CDK2 Complex* , 1999, The Journal of Biological Chemistry.
[98] E. Enmark,et al. Oestrogen receptors – an overview , 1999, Journal of internal medicine.
[99] A. Jazaeri,et al. Expression of Estrogen Receptor α mRNA and Protein Variants in Human Endometrial Carcinoma , 1999 .
[100] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[101] M. Dowsett,et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[102] Jidong Liu,et al. Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins , 1998, Oncogene.
[103] W. Reith,et al. Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle , 1998, Oncogene.
[104] Robert A. Weinberg,et al. Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.
[105] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[106] M. Garabedian,et al. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[107] M. Ewen,et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 , 1997, Molecular and cellular biology.
[108] V. Moudgil,et al. Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells , 1997, Oncogene.
[109] G. Sledge,et al. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.
[110] S. Nass,et al. Defining a role for c-Myc in breast tumorigenesis , 1997, Breast Cancer Research and Treatment.
[111] L. Meijer,et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. , 1997, Journal of medicinal chemistry.
[112] R. Bernards,et al. CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.
[113] F. Kern,et al. Estrogen induction of TGF-α is mediated by an estrogen response element composed of two imperfect palindromes , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[114] A. Bowcock,et al. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. , 1996, Oncogene.
[115] P. Jeffrey,et al. Structural basis of cyclin-dependent kinase activation by phosphorylation , 1996, Nature Structural Biology.
[116] D. Horsfall,et al. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[117] B. Katzenellenbogen,et al. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. , 1996, Chemistry & biology.
[118] B. Katzenellenbogen,et al. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.
[119] K. Umesono,et al. The nuclear receptor superfamily: The second decade , 1995, Cell.
[120] Daniel Metzger,et al. Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.
[121] H. Nguyen,et al. Hormone-dependent regulation of BRCA1 in human breast cancer cells. , 1995, Cancer research.
[122] M. Obeyesekere,et al. A model of the G1 phase of the cell cycle incorporating cyclin E/cdk2 complex and retinoblastoma protein. , 1995, Oncogene.
[123] S. Elledge,et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast , 1995, Cell.
[124] D. Lannigan,et al. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. , 1995, Molecular endocrinology.
[125] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[126] R. Weinberg,et al. A cyclin associated with the CDK-activating kinase MO15 , 1994, Nature.
[127] J. Blow,et al. Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.
[128] David O. Morgan,et al. A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase , 1994, Cell.
[129] B. Katzenellenbogen,et al. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. , 1994, The Journal of biological chemistry.
[130] S. van den Heuvel,et al. Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.
[131] K. Korach,et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[132] J. Labbé,et al. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin‐dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. , 1993, The EMBO journal.
[133] M. Ewen,et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. , 1993, Genes & development.
[134] P. Chambon,et al. Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region. , 1993, The EMBO journal.
[135] K. Keyomarsi,et al. Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[136] R. Shiu,et al. Mechanism of estrogen activation of c-myc oncogene expression. , 1992, Oncogene.
[137] B. Katzenellenbogen. Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. , 1991, Journal of the National Cancer Institute.
[138] James M. Roberts,et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family , 1991, Cell.
[139] J. Pines,et al. Cyclins: wheels within wheels. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[140] V. Jordan,et al. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. , 1990, Cancer research.
[141] J. Ham,et al. Regulation of gene expression by nuclear hormone receptors. , 1989, Current opinion in cell biology.
[142] M. Schauer,et al. DNA regulatory elements for steroid hormones. , 1989, Journal of steroid biochemistry.
[143] T. Hunt,et al. The role of cyclin synthesis, modification and destruction in the control of cell division , 1989, Journal of Cell Science.
[144] R. Shiu,et al. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. , 1987, Cancer research.
[145] B. Katzenellenbogen,et al. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. , 1987, Cancer research.
[146] Stephen H. Friend,et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.
[147] P. Chambon,et al. Cloning of the human estrogen receptor cDNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[148] M. Malumbres,et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. , 2015, Blood.
[149] Massimo Cristofanilli,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[150] J. Węsierska‐Gądek,et al. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms. , 2011, Current pharmaceutical design.
[151] D. Santamaría,et al. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. , 2006, Frontiers in bioscience : a journal and virtual library.
[152] R. Sutherland,et al. Cyclins and breast cancer , 2005, Journal of Mammary Gland Biology and Neoplasia.
[153] S. Fuqua,et al. Estrogen Receptor Variants , 2004, Journal of Mammary Gland Biology and Neoplasia.
[154] Anne-Marie Brun-Zinkernagel,et al. Mitochondrial localization of estrogen receptor beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[155] D. Wolf,et al. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain , 2004, Breast Cancer Research and Treatment.
[156] J. Frasor,et al. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. , 2003, Endocrinology.
[157] K. Dahlman-Wright,et al. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. , 2003, Molecular endocrinology.
[158] R. McPherson,et al. Linkage of Rapid Estrogen Action to MAPK Activation by ER-Shc Association and Shc Pathway Activation , 2001 .
[159] S. Safe,et al. Differential gene expression in response to methoxychlor and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice. , 2001, Toxicological Sciences.
[160] A. Jazaeri,et al. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. , 1999, Gynecologic oncology.
[161] M. Ewen,et al. Cyclin D 1 Stimulation of Estrogen Receptor Transcriptional Activity Independent of cdk 4 † , 1997 .
[162] D O Morgan,et al. Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.
[163] P. Nurse,et al. Animal cell cycles and their control. , 1992, Annual review of biochemistry.